Drugs / ARTEGENE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05071222 | Jul 2023 → Nov 2041 expected | severe combined immunodeficiency due to DCLRE1C deficiency | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARTEGENE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05071222 ↗ |
| Route | Intravenous | “single intravenous infusion of ARTEGENE drug product at D0” NCT05071222 ↗ |